Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901326 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL332530 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL3825 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL1070875 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Ammonia Solution, Strong SCHEMBL2074263 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL27882040 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL1888091 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL3935755 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Cyanide SCHEMBL28515924 | 0.94 | CDK5 (0.38) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL17856475 | 0.92 | NR1I3 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103733065-B | Molecular diagnostic test for cancer | 阿尔玛克诊断有限公司 | 2017-12-15 | — | — | CN | claimed |
| US-8404829-B2 | Predictive and therapeutic markers in ovarian cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-26 | — | — | US | claimed |
| US-20230348999-A1 | STRATIFICATION AND PROGNOSIS OF CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-11-02 | — | — | US | disclosed |
| EP-2975399-B1 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTIC SERVICES LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| CN-114028380-A | Application of naringenin in preparing medicine for treating intestinal flora disorder caused by ovarian cancer | 哈尔滨医科大学 | 2022-02-11 | — | — | CN | disclosed |
| US-11091809-B2 | Molecular diagnostic test for cancer | ALMAC DIAGNOSTIC SERVICES LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-2619574-B1 | MOLECULAR TEST FOR PREDICTING RESPONSIVENESS TO DNA-DAMAGE THERAPEUTIC AGENTS IN INDIVIDUALS HAVING CANCER | ALMAC DIAGNOSTIC SERVICES LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-20200308650-A1 | STRATIFICATION AND PROGNOSIS OF CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-10-01 | — | — | US | disclosed |
| EP-3325653-B1 | GENE SIGNATURE FOR IMMUNE THERAPIES IN CANCER | ALMAC DIAGNOSTIC SERVICES LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3612643-A1 | STRATIFICATION AND PROGNOSIS OF CANCER | The University of British Columbia (CA) | 2020-02-26 | — | — | EP | disclosed |
| EP-2925885-B1 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTIC SERVICES LTD (GB) | 2020-02-05 | — | — | EP | disclosed |
| WO-2015118353-A1 | MOLECULAR DIAGNOSTIC TEST FOR PREDICTING RESPONSE TO ANTI-ANGIOGENIC DRUGS AND PROGNOSIS OF CANCER | ALMAC DIAGNOSTICS LIMITED (GB) | 2015-08-13 | — | — | WO | disclosed |
| US-20140342924-A1 | Molecular Diagnostic Test for Cancer | ALMAC DIAGNOSTICS LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| WO-2014087156-A1 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTICS LIMITED (GB) | 2014-06-12 | — | — | WO | disclosed |
| US-20140051591-A1 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTICS LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140031260-A1 | Molecular Diagnostic Test for Cancer | ALMAC DIAGNOSTIC SERVICES LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| CN-103299188-A | Molecular diagnostic test for cancer | ALMAC DIAGNOSTICS LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2619574-A2 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | Almac Diagnostics Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012167278-A1 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTICS LIMITED (GB) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012037378-A2 | MOLECULAR DIAGNOSTIC TEST FOR CANCER | ALMAC DIAGNOSTICS LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |